Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Non Operating Income: 2020-2025

Historic Non Operating Income for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to -$6.1 million.

  • Xeris Biopharma Holdings' Non Operating Income rose 0.96% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.4 million, marking a year-over-year decrease of 24.40%. This contributed to the annual value of -$23.5 million for FY2024, which is 20.33% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Non Operating Income stood at -$6.1 million for Q3 2025, which was up 4.68% from -$6.4 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Non Operating Income high stood at $1.9 million for Q4 2022, and its period low was -$7.6 million during Q3 2023.
  • Its 3-year average for Non Operating Income is -$5.6 million, with a median of -$6.1 million in 2025.
  • Data for Xeris Biopharma Holdings' Non Operating Income shows a peak YoY increase of 175.51% (in 2022) and a maximum YoY decrease of 340.28% (in 2022) over the last 5 years.
  • Xeris Biopharma Holdings' Non Operating Income (Quarterly) stood at -$2.5 million in 2021, then spiked by 175.51% to $1.9 million in 2022, then tumbled by 299.00% to -$3.8 million in 2023, then crashed by 79.45% to -$6.8 million in 2024, then rose by 0.96% to -$6.1 million in 2025.
  • Its last three reported values are -$6.1 million in Q3 2025, -$6.4 million for Q2 2025, and -$6.1 million during Q1 2025.